Buy Cardiogen Research Peptide

What is Cardiogen?

Cardiogen is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Arg) from the Russian peptide bioregulator program, designed to target heart tissue. It is studied in laboratory research for its effects on heart-muscle cell signaling and gene activity.

• A short synthetic peptide (Ala-Glu-Asp-Arg) from the Russian bioregulator program
• Studied in laboratory research for its effects on heart-muscle cell signaling and gene activity
• One of a family of short peptides each studied in a specific tissue type
• Investigated alongside Bronchogen, Epithalon and other organ-specific bioregulators

For research use only. Not approved for human therapeutic use.

Cardiogen, also known by its tetrapeptide designation AEDR (Ala-Glu-Asp-Arg), is a synthetic tetrapeptide bioregulator with a molecular weight of 489.48 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Cardiogen was designed based on peptide fractions associated with cardiac tissue. Its sequence, Ala-Glu-Asp-Arg, extends the AED core motif shared across the bioregulator series with a C-terminal arginine residue, a basic amino acid containing the guanidinium group. This structural variation within the AED-based tetrapeptide series, where the C-terminal residue defines organ specificity, is a distinctive feature of the Khavinson bioregulator design framework. Produced via solid-phase peptide synthesis, Cardiogen is associated with cardiac tissue gene expression and myocardial signalling pathways.

Cardiogen belongs to the ultra-short peptide bioregulators developed by Professor Vladimir Khavinson. In common with related bioregulator peptides such as Epithalon (AEDG), Pinealon (EDR) and Cortagen (AEDP), Cardiogen has been proposed to exert its biological activity through direct, sequence-selective interaction with DNA rather than conventional cell-surface receptor-mediated signalling. In vitro research using organotypic culture has documented that Cardiogen stimulates the development of myocardial tissue explants, with a measurable effect on tissue growth that differs between preparations from young and old rats [1]. At the level of the aging cardiovascular system, peptide bioregulators of this class have been reviewed in the broader context of cellular senescence and inflammaging in cardiovascular tissue [2], making Cardiogen a reference compound in preclinical cardiovascular research examining ultra-short peptide-bioregulator modulation of myocardial tissue development, cardiac signalling, and age-related changes in cardiovascular tissue.

Cardiogen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Chalisova NI, Lesniak VV, Balykina NA, Urt’eva SA, Urt’eva TA, Sukhonos IA, et al. [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]. Adv Gerontol. 2009;22(3):409–13. .PubMed PMID: 202101902Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. Cells. 2022 Dec 27;12(1):106. ; PubMed Central PMCID: PMC9818427.PubMed PMID: 36611900

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Cardiogen, also known by its tetrapeptide designation AEDR (Ala-Glu-Asp-Arg), is a synthetic tetrapeptide bioregulator with a molecular weight of 489.48 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Cardiogen was designed based on peptide fractions associated with cardiac tissue. Its sequence, Ala-Glu-Asp-Arg, extends the AED core motif shared across the bioregulator series with a C-terminal arginine residue, a basic amino acid containing the guanidinium group. This structural variation within the AED-based tetrapeptide series, where the C-terminal residue defines organ specificity, is a distinctive feature of the Khavinson bioregulator design framework. Produced via solid-phase peptide synthesis, Cardiogen is associated with cardiac tissue gene expression and myocardial signalling pathways.

Cardiogen belongs to the ultra-short peptide bioregulators developed by Professor Vladimir Khavinson. In common with related bioregulator peptides such as Epithalon (AEDG), Pinealon (EDR) and Cortagen (AEDP), Cardiogen has been proposed to exert its biological activity through direct, sequence-selective interaction with DNA rather than conventional cell-surface receptor-mediated signalling. In vitro research using organotypic culture has documented that Cardiogen stimulates the development of myocardial tissue explants, with a measurable effect on tissue growth that differs between preparations from young and old rats [1]. At the level of the aging cardiovascular system, peptide bioregulators of this class have been reviewed in the broader context of cellular senescence and inflammaging in cardiovascular tissue [2], making Cardiogen a reference compound in preclinical cardiovascular research examining ultra-short peptide-bioregulator modulation of myocardial tissue development, cardiac signalling, and age-related changes in cardiovascular tissue.

Cardiogen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Chalisova NI, Lesniak VV, Balykina NA, Urt’eva SA, Urt’eva TA, Sukhonos IA, et al. [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]. Adv Gerontol. 2009;22(3):409–13. .PubMed PMID: 202101902Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. Cells. 2022 Dec 27;12(1):106. ; PubMed Central PMCID: PMC9818427.PubMed PMID: 36611900

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight489.49 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-CARDIOGEN-3512

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Cardiogen, also known by its tetrapeptide designation AEDR (Ala-Glu-Asp-Arg), is a synthetic tetrapeptide bioregulator with a molecular weight of 489.48 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Cardiogen was designed based on peptide fractions associated with cardiac tissue. Its sequence, Ala-Glu-Asp-Arg, extends the AED core motif shared across the bioregulator series with a C-terminal arginine residue, a basic amino acid containing the guanidinium group. This structural variation within the AED-based tetrapeptide series, where the C-terminal residue defines organ specificity, is a distinctive feature of the Khavinson bioregulator design framework. Produced via solid-phase peptide synthesis, Cardiogen is associated with cardiac tissue gene expression and myocardial signalling pathways.

Cardiogen belongs to the ultra-short peptide bioregulators developed by Professor Vladimir Khavinson. In common with related bioregulator peptides such as Epithalon (AEDG), Pinealon (EDR) and Cortagen (AEDP), Cardiogen has been proposed to exert its biological activity through direct, sequence-selective interaction with DNA rather than conventional cell-surface receptor-mediated signalling. In vitro research using organotypic culture has documented that Cardiogen stimulates the development of myocardial tissue explants, with a measurable effect on tissue growth that differs between preparations from young and old rats [1]. At the level of the aging cardiovascular system, peptide bioregulators of this class have been reviewed in the broader context of cellular senescence and inflammaging in cardiovascular tissue [2], making Cardiogen a reference compound in preclinical cardiovascular research examining ultra-short peptide-bioregulator modulation of myocardial tissue development, cardiac signalling, and age-related changes in cardiovascular tissue.

Cardiogen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Chalisova NI, Lesniak VV, Balykina NA, Urt’eva SA, Urt’eva TA, Sukhonos IA, et al. [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]. Adv Gerontol. 2009;22(3):409–13. .PubMed PMID: 202101902Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. Cells. 2022 Dec 27;12(1):106. ; PubMed Central PMCID: PMC9818427.PubMed PMID: 36611900

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight489.49 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-CARDIOGEN-3512

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.